Compare Wahed FTSE USA Shariah ETF (HLAL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Wahed FTSE USA Shariah ETF trades at $71.24, while Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B). The key difference: Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals.
| HLAL | VRTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $73.60 | $529.59 |
52-Week Low | $54.05 | $366.54 |
Market Cap | — | $121.95B |
Enterprise Value | — | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $70.22, down 0.17% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock faces resistance at $71 and support at $70. Key financial ratios including P/E, P/S, and ROE are unavailable in the current dataset, limiting fundamental assessment. A small dividend of $0.02 is scheduled for June 2026.
The outlook remains cautious due to weak technical momentum and incomplete fundamental data. Investment opportunity hinges on upcoming financial disclosures to validate valuation. Primary risks include market volatility and lack of recent business updates. Analyst sentiment appears neutral to bearish given the technical configuration.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
